Biopharmaceutical

Charles River Laboratories has revealed plans to open Charles River Accelerator and Development Lab (CRADL) locations in Seattle and Philadelphia, expanding the company’s contract vivarium space for the biopharmaceutical industry. CRADL Seattle is opening this September as Charles River’s most recent investment in Seattle, providing flexible vivarium space and on-demand in vivo study support services. […]

Gary Connors, Partner at business consulting company Oliver Wight EAME looks at some of the most important factors that will affect the pharmaceutical industry going forward.   We advise all our clients to make assumptions and think about scenarios that could affect their business at least five years in advance. I’m not a futurist, neither […]

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research.   Japan continues to be one of the largest pharmaceutical markets in the world, despite what the International Trade Administration described as […]

Regulus Therapeutics, a biopharmaceutical company focused on the discovery and development of medicines targeting microRNAs, has appointed Mohammad Ahmadian as Vice President of Chemistry and Pharmaceutical Development.   The role  In his role, Dr. Ahmadian will assist in managing research and development of the company’s drug candidates, including RGLS8429, which is being developed for patients with […]

Waters Corporation and Sartorius have partnered to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.   The partnership will implement the BioAccord LC-MS System from Waters as a new bioprocess analyser with data connectivity to Sartorius’ Ambr multi-parallel bioreactor systems to deliver mass spectral […]

Leif Pedersen, President, Software, and David Lowis, Executive Director of Scientific Informatics at Certara, explain how scientific intelligence can refine and increase the effectiveness of critical decision points in drug discovery. Strong scientific intelligence capabilities are essential building blocks for a scientific informatics strategy and will increase the effectiveness of the drug development life cycle. […]

The route to market for biosimilars places strong emphasis on characterisation tools for establishing comparability between biosimilar and innovator products.   Addressing analytical challenges in fast-forwarding biosimilar development processes requires Implementing sophisticated analytical instruments with advanced technologies. The ICH Q6B, cited by both EMA and FDA, highlights electrophoretic data as an important part of the molecule’s full structural characterisation.   […]

Inmagene Biopharmaceuticals and Affibody have dosed the first patient in the global ASPIRE Phase II trial evaluating izokibep (IMG-020 or ABY-035) for the treatment of ankylosing spondylitis (AS).  “Dosing the first patient in the global Phase II AS trial is an important milestone for the izokibep programme,” said Dr. Jean-Louis Saillot, Inmagene’s Chief Development Officer. “Working closely with our partner Affibody, the Inmagene team is excited to […]

The President of the UK’s Association of the British Pharmaceutical Industry (ABPI) has announced that its 2021 Code of Practice puts new emphasis on the ABPI’s principles. “We want everyone in pharmaceutical companies to live and breathe these from leadership teams and commercial leads to admin assistants and research scientists. It’s all of our responsibility […]

In this latest DDW whitepaper, brought to you by PerkinElmer Informatics, John Conway, is Chief Visioneer Officer at 20/15 Visioneers, tackles defining “What Makes a Great BioELN” in this thoughtful and informative industry perspective. The whitepaper covers the six high-level workflows a great BioELN must include; what the team personas who must get utility from […]

The latest DDW Sponsored Sitting Down With podcast features Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. Listen to hear Mathur discuss the company philosophy, how the pandemic has affected the business, its partnership experience and […]

The latest DDW Sitting Down With podcast features Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. The company has created some successful partnerships and she explains what these look like, why they have been fruitful, and […]

The Chief Executive of the UK’s Association of the British Pharmaceutical Industry (ABPI), Richard Torbett, has stressed the importance of investment in research in response to the Queen’s Speech delivery. “The response to the pandemic has shown just how critical the UK’s pharmaceutical industry is to our country’s future and the Queen’s Speech has set […]

GW Pharmaceuticals has received the Queen’s Award for Enterprise 2021 in the Innovation category, recognising the company’s work to harness cannabinoid science to create the world’s first regulatory approved, prescription cannabis-based medicines. Since its inception in 1998, GW worked on the development, manufacture and commercialisation of regulatory approved cannabis-based medicines. Globally, GW has invested more […]

Viswa Colluru, PhD, founder and CEO of Enveda Biosciences talks to Lu Rahman about the company’s chemical search engine and its work harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges.  LR: Describe what Enveda does and some of its current work / initiatives. VC: Enveda is building the first high-resolution […]

Evotec has launched beLAB2122, a US$20 million BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) collaboration with Bristol-Myers Squibb. beLAB2122 brings together academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. Supported by […]